Mining the genomes of exceptional responders

Nature Reviews Cancer

Volumn 14, Issue 5, 2014, Pages 291-292

  Chang, David K ^a,b,c,d,e   Grimmond, Sean M ^a,f   Evans, T R Jeffry ^a   Biankin, Andrew V ^a,b,c,d,e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEUROFIBROMIN; TUBERIN; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER GENETICS; CANCER SURVIVAL; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MOLECULAR PATHOLOGY; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIPLE NEGATIVE BREAST CANCER; DRUG RESISTANCE; GENETICS; GENOME; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

DRUG RESISTANCE, NEOPLASM; GENOME; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHENOTYPE; TREATMENT OUTCOME;

EID: 84899645673     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3723     Document Type: Review

References (7)

1. Avicenna The Canon of Medicine (Persia, 1025).
2. Willyard, C. 'Basket studies' will hold intricate data for cancer drug approvals. Nature Med. 19, 655-655 (2013).
3. Stewart, D. J. & Kurzrock, R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 13, 193 (2013).
4. Chou, A. et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 5, 78 (2013).
5. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
6. Chang, K. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genet. 45, 1113-1120 (2013).
7. Riley, W. T., Glasgow, R. E., Etheredge, L. & Abernethy, A. P. Rapid, responsive, relevant (R3) research: a call for a rapid learning health research enterprise. Clin. Transl. Med. 2, 10 (2013).